

Active Pharmaceutical Ingredients

PRODUCT NAME	CATEGORY	REGULATORY APPROVAL		
		USDMF	CEP/EDMF	Others
COMMERCIAL APIs				
Atropine Sulfate	Mydriatic and Cycloplegic	#029605	EDMF; CEP	NMPA (China), TGA (Australia), CBPF (Brazil), MFDS (Korea) & Filed in Health Canada
Clopidogrel Besylate (in tie up with Pharmathen)	Antiplatelet		EDMF	
Clopidogrel Bisulfate (Form II)	Antiplatelet		EDMF; CEP (Under Review)	MFDS (Korea)
Dexketoprofen Trometamol	Analgesic	#026959	EDMF	Russia, MFDS (Korea) & CBPF (Brazil)
Diethyl Carbamazine Citrate	Anthelmintic			WHO (APIMF216)
Febuxostat (in tie up with Pharmathen)	Xanthine Oxidase Inhibitor		EDMF	
Homatropine Hydrobromide	Anticholinergic medication Mydriatic and Cycloplegic		EDMF	
Homatropine Methylbromide	Anticholinergic medication Mydriatic and Cycloplegic	#023963	EDMF	CBPF (Brazil)
Ketorolac Tromethamine	Analgesic		EDMF	Russia, MFDS (Korea) & ANVISA (Brazil) Filed in Health Canada
Levofloxacin Hemihydrate	Broad Spectrum Antibiotic		EDMF; CEP	
Nitisinone	4-hydroxyphenylpyruvate Dioxygenase	#035810		
Obidoxime Hydrochloride	Antidote: Cholinesterase Reactivator		EDMF	
Pregabalin (in tie up with Pharmathen)	Anticonvulsant Drug			
Probenecid	Treatment of Gout and Hyperuricemia	#036234		
Papaverine HCL	Erectile Dysfunction	Q3 2024		China FDA (Under Review)
Ketoprofen	Non-Steroidal Anti-Inflammatory Drug, or NSAID		EDMF; CEP	CBPF (Brazil)
Vildagliptin (in tie up with Pharmathen)	Anti-Hyperglycemic Agent			
Rebamipide	Treatment of Gastric Ulcers			JDMF filed
Ipratropium bromide	Bronchodilator		EDMF; CEP	CBPF (Brazil)
Ibandronate Sodium (in tie up with Pharmathen)	Treatment of Osteoporosis			
APIs LAUNCHING				
Carglumic Acid	Treatment of Hyperammonaemia	Q3 2024		NMPA: Q3 2024
Tiotropium Bromide	Bronchodilator	Q3 2024	CEP: Q3 2024	NMPA: Q3 2024
Dapagliflozin	Type-II Antidiabetic	Q4 2024		
Ticagrelor	Antiplatelet	Q4 2024		
Empagliflozin	Antidiabetic	Q2 2025		
APIs UNDER DEVELOPMENT				
Bempedoic acid	Lipid Lowering Agent	Q2 2025		
Tegoprazan	Treatment of acid-related GI diseases	Q2 2025		
Ozanimod	Treatment of relapsing Multiple Sclerosis and Ulcerative Colitis	Q3 2025		
Daprodustat	Treatment of Anaemia due to CKD	Q1 2025		

Disclaimer : Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. The liability of any sale into such protected markets is at buyer's risk.